Altre lingue GeoVax Labs, Inc.

Azioni

GOVX

US3736786068

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 12/07/2024			Variaz. 5gg	Var. 1 gen.
2,78 ^USD	-4,14%		-0,71%	-48,66%

18/06	Geovax Labs, Inc. riceve il premio del Progetto Barda NextGen per condurre lo studio clinico di Fase 2B che valuterà il candidato vaccino Covid-19 di nuova generazione, GEO-CM04S1.	CI
07/06	I principali ribassisti del pre-mercato	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

GeoVax Labs : to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At the Market Form 8 K	12/07
GeoVax Provides First Half 2024 Business Update	09/07
GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA	27/06
GeoVax Labs : Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next Generation COVID 19 Vaccine Candidate, GEO CM04S1 Form 8 K	19/06
Geovax Labs, Inc. Receives Barda Project NextGen Award to Conduct Phase 2B Clinical Study Evaluating the Company's Next-Generation Covid-19 Vaccine Candidate, GEO-CM04S1	18/06
GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1	18/06
Top Premarket Decliners	07/06
GeoVax to Present at BIO International Convention 2024	30/05
GeoVax Labs : to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market - Form 8-K	21/05
GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market	17/05
GeoVax Labs : Reports First Quarter 2024 Financial Results and Provides Business Update - Form 8-K	15/05
GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update	14/05
GeoVax Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024	07/05
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine	04/04
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress	28/03
GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress	28/03
GeoVax to Present at the 36th Annual Roth Conference	12/03
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System	06/03
GeoVax Labs, Inc. Achieves Milestone in Transition to Commercially Validated Manufacturing System	06/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue GeoVax Labs, Inc.

Azioni

GOVX

US3736786068

Altre lingue

Filtri